These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 27053714)
1. Lamotrigine use in pregnancy and risk of orofacial cleft and other congenital anomalies. Dolk H; Wang H; Loane M; Morris J; Garne E; Addor MC; Arriola L; Bakker M; Barisic I; Doray B; Gatt M; Kallen K; Khoshnood B; Klungsoyr K; Lahesmaa-Korpinen AM; Latos-Bielenska A; Mejnartowicz JP; Nelen V; Neville A; O'Mahony M; Pierini A; Rißmann A; Tucker D; Wellesley D; Wiesel A; de Jong-van den Berg LT Neurology; 2016 May; 86(18):1716-25. PubMed ID: 27053714 [TBL] [Abstract][Full Text] [Related]
2. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Dolk H; Jentink J; Loane M; Morris J; de Jong-van den Berg LT; Neurology; 2008 Sep; 71(10):714-22. PubMed ID: 18650491 [TBL] [Abstract][Full Text] [Related]
3. Preliminary results on pregnancy outcomes in women using lamotrigine. Tennis P; Eldridge RR; Epilepsia; 2002 Oct; 43(10):1161-7. PubMed ID: 12366730 [TBL] [Abstract][Full Text] [Related]
4. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Holmes LB; Baldwin EJ; Smith CR; Habecker E; Glassman L; Wong SL; Wyszynski DF Neurology; 2008 May; 70(22 Pt 2):2152-8. PubMed ID: 18448870 [TBL] [Abstract][Full Text] [Related]
5. Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study. Jentink J; Dolk H; Loane MA; Morris JK; Wellesley D; Garne E; de Jong-van den Berg L; BMJ; 2010 Dec; 341():c6581. PubMed ID: 21127116 [TBL] [Abstract][Full Text] [Related]
6. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Cunnington MC; Weil JG; Messenheimer JA; Ferber S; Yerby M; Tennis P Neurology; 2011 May; 76(21):1817-23. PubMed ID: 21606453 [TBL] [Abstract][Full Text] [Related]
7. Valproic acid monotherapy in pregnancy and major congenital malformations. Jentink J; Loane MA; Dolk H; Barisic I; Garne E; Morris JK; de Jong-van den Berg LT; N Engl J Med; 2010 Jun; 362(23):2185-93. PubMed ID: 20558369 [TBL] [Abstract][Full Text] [Related]
8. Selective serotonin reuptake inhibitor antidepressant use in first trimester pregnancy and risk of specific congenital anomalies: a European register-based study. Wemakor A; Casson K; Garne E; Bakker M; Addor MC; Arriola L; Gatt M; Khoshnood B; Klungsoyr K; Nelen V; O'Mahoney M; Pierini A; Rissmann A; Tucker D; Boyle B; de Jong-van den Berg L; Dolk H Eur J Epidemiol; 2015 Nov; 30(11):1187-98. PubMed ID: 26148560 [TBL] [Abstract][Full Text] [Related]
9. Topiramate use early in pregnancy and the risk of oral clefts: A pregnancy cohort study. Hernandez-Diaz S; Huybrechts KF; Desai RJ; Cohen JM; Mogun H; Pennell PB; Bateman BT; Patorno E Neurology; 2018 Jan; 90(4):e342-e351. PubMed ID: 29282333 [TBL] [Abstract][Full Text] [Related]
10. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Tomson T; Battino D; Bonizzoni E; Craig J; Lindhout D; Sabers A; Perucca E; Vajda F; Lancet Neurol; 2011 Jul; 10(7):609-17. PubMed ID: 21652013 [TBL] [Abstract][Full Text] [Related]
11. Lamotrigine and the risk of malformations in pregnancy. Cunnington M; Tennis P; Neurology; 2005 Mar; 64(6):955-60. PubMed ID: 15781807 [TBL] [Abstract][Full Text] [Related]
12. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. Campbell E; Kennedy F; Russell A; Smithson WH; Parsons L; Morrison PJ; Liggan B; Irwin B; Delanty N; Hunt SJ; Craig J; Morrow J J Neurol Neurosurg Psychiatry; 2014 Sep; 85(9):1029-34. PubMed ID: 24444855 [TBL] [Abstract][Full Text] [Related]
13. Newer anticonvulsants: lamotrigine, topiramate and gabapentin. Holmes LB; Hernandez-Diaz S Birth Defects Res A Clin Mol Teratol; 2012 Aug; 94(8):599-606. PubMed ID: 22730257 [TBL] [Abstract][Full Text] [Related]
14. Teratogenicity of lamotrigine. Shor S; Koren G; Nulman I Can Fam Physician; 2007 Jun; 53(6):1007-9. PubMed ID: 17872777 [TBL] [Abstract][Full Text] [Related]
15. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Cunnington M; Ferber S; Quartey G; Epilepsia; 2007 Jun; 48(6):1207-10. PubMed ID: 17381445 [TBL] [Abstract][Full Text] [Related]
16. Corticosteroid use during pregnancy and risk of orofacial clefts. Hviid A; Mølgaard-Nielsen D CMAJ; 2011 Apr; 183(7):796-804. PubMed ID: 21482652 [TBL] [Abstract][Full Text] [Related]
17. Epilepsy and pregnancy: lamotrigine as main drug used. Sabers A; Dam M; A-Rogvi-Hansen B; Boas J; Sidenius P; Laue Friis M; Alving J; Dahl M; Ankerhus J; Mouritzen Dam A Acta Neurol Scand; 2004 Jan; 109(1):9-13. PubMed ID: 14653845 [TBL] [Abstract][Full Text] [Related]
18. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Reiff-Eldridge R; Heffner CR; Ephross SA; Tennis PS; White AD; Andrews EB Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):159-63. PubMed ID: 10649172 [TBL] [Abstract][Full Text] [Related]
20. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations. Charlton RA; Weil JG; Cunnington MC; Ray S; de Vries CS Drug Saf; 2011 Feb; 34(2):157-71. PubMed ID: 21247222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]